KR102340010B1 - 항균제를 포함하는 제약학적 조성물 - Google Patents

항균제를 포함하는 제약학적 조성물 Download PDF

Info

Publication number
KR102340010B1
KR102340010B1 KR1020167013330A KR20167013330A KR102340010B1 KR 102340010 B1 KR102340010 B1 KR 102340010B1 KR 1020167013330 A KR1020167013330 A KR 1020167013330A KR 20167013330 A KR20167013330 A KR 20167013330A KR 102340010 B1 KR102340010 B1 KR 102340010B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
compound
formula
cefepime
acceptable derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167013330A
Other languages
English (en)
Korean (ko)
Other versions
KR20160072254A (ko
Inventor
사친 브하그와트
마헤쉬 비탈바이 파텔
Original Assignee
욱크하르트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 욱크하르트 리미티드 filed Critical 욱크하르트 리미티드
Publication of KR20160072254A publication Critical patent/KR20160072254A/ko
Application granted granted Critical
Publication of KR102340010B1 publication Critical patent/KR102340010B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
KR1020167013330A 2013-10-22 2014-10-22 항균제를 포함하는 제약학적 조성물 Active KR102340010B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3309/MUM/2013 2013-10-22
PCT/IB2014/065522 WO2015059643A1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
IN3309MU2013 IN2013MU03309A (cg-RX-API-DMAC10.html) 2013-10-22 2014-10-22

Publications (2)

Publication Number Publication Date
KR20160072254A KR20160072254A (ko) 2016-06-22
KR102340010B1 true KR102340010B1 (ko) 2021-12-16

Family

ID=52003012

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167013330A Active KR102340010B1 (ko) 2013-10-22 2014-10-22 항균제를 포함하는 제약학적 조성물

Country Status (18)

Country Link
US (1) US9827235B2 (cg-RX-API-DMAC10.html)
EP (1) EP3060213B1 (cg-RX-API-DMAC10.html)
JP (2) JP2016538258A (cg-RX-API-DMAC10.html)
KR (1) KR102340010B1 (cg-RX-API-DMAC10.html)
CN (2) CN106102741A (cg-RX-API-DMAC10.html)
AU (1) AU2014338612C1 (cg-RX-API-DMAC10.html)
BR (1) BR112016008979B1 (cg-RX-API-DMAC10.html)
CA (1) CA2928364C (cg-RX-API-DMAC10.html)
DK (1) DK3060213T3 (cg-RX-API-DMAC10.html)
ES (1) ES2902456T3 (cg-RX-API-DMAC10.html)
HU (1) HUE057504T2 (cg-RX-API-DMAC10.html)
IN (1) IN2013MU03309A (cg-RX-API-DMAC10.html)
MX (1) MX375934B (cg-RX-API-DMAC10.html)
NZ (1) NZ719215A (cg-RX-API-DMAC10.html)
PL (1) PL3060213T3 (cg-RX-API-DMAC10.html)
PT (1) PT3060213T (cg-RX-API-DMAC10.html)
RU (1) RU2702361C2 (cg-RX-API-DMAC10.html)
WO (1) WO2015059643A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030733A1 (en) * 2011-08-27 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465428B1 (en) * 1999-08-27 2002-10-15 Aventis Pharma S.A. Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
MX2007007235A (es) * 2004-12-17 2007-10-19 Venus Remedies Ltd Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones.
RU2366450C1 (ru) * 2008-08-04 2009-09-10 Валентина Васильевна Малиновская Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
CA2842777C (en) * 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
HUE046893T2 (hu) * 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
AU2014206087A1 (en) * 2013-01-14 2015-05-28 Wockhardt Limited Compositions and methods for treating bacterial infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030733A1 (en) * 2011-08-27 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections

Also Published As

Publication number Publication date
CN113577084A (zh) 2021-11-02
IN2013MU03309A (cg-RX-API-DMAC10.html) 2015-07-17
AU2014338612B2 (en) 2019-12-19
PL3060213T3 (pl) 2022-02-14
US20160303104A1 (en) 2016-10-20
KR20160072254A (ko) 2016-06-22
DK3060213T3 (da) 2022-01-03
WO2015059643A1 (en) 2015-04-30
RU2016115376A (ru) 2017-11-28
NZ719215A (en) 2020-04-24
PT3060213T (pt) 2021-12-24
CA2928364A1 (en) 2015-04-30
MX375934B (es) 2025-03-07
ES2902456T3 (es) 2022-03-28
RU2702361C2 (ru) 2019-10-08
CA2928364C (en) 2021-11-23
CN106102741A (zh) 2016-11-09
AU2014338612C1 (en) 2020-09-24
RU2016115376A3 (cg-RX-API-DMAC10.html) 2018-07-02
US9827235B2 (en) 2017-11-28
JP2019116508A (ja) 2019-07-18
HUE057504T2 (hu) 2022-05-28
BR112016008979A2 (cg-RX-API-DMAC10.html) 2017-08-01
MX2016005161A (es) 2016-10-05
EP3060213A1 (en) 2016-08-31
JP2016538258A (ja) 2016-12-08
BR112016008979B1 (pt) 2023-04-25
EP3060213B1 (en) 2021-10-13
JP6886996B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
JP6525999B2 (ja) 抗菌性組成物
JP6886996B2 (ja) 抗菌剤を含む医薬組成物
US9789097B2 (en) Pharmaceutical compositions comprising antibacterial agents
JP2017506240A (ja) 抗菌剤を含む医薬組成物
US20170000775A1 (en) Pharmaceutical compositions comprising antibacterial agents
US20160287571A1 (en) Pharmaceutical compositions comprising antibacterial agents
AU2014338612A1 (en) Pharmaceutical compositions comprising antibacterial agents
EP3131555A1 (en) Pharmaceutical compositions comprising antibacterial agents
US20170151221A1 (en) Pharmaceutical compositions comprising cefepime or sulbactam
WO2018193368A1 (en) Antibacterial compositions
KR20160072262A (ko) 항균제를 포함하는 제약학적 조성물
KR20160072253A (ko) 항균제를 포함하는 제약학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5